ProMIS Neurosciences Files 8-K: Material Agreement & Equity Sales

TL;DR

ProMIS Neurosciences inked a big deal and sold some stock on July 28th. Check the 8-K.

AI Summary

ProMIS Neurosciences Inc. announced on July 28, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial position and future operations.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• July 28, 2025 (date) — Date of earliest event reported
• 001-41429 (company) — Commission File Number
• 1920 Yonge Street, Toronto, Ontario (location) — Business Address

FAQ

From the Filing

0001558370-25-009636.txt : 20250728 0001558370-25-009636.hdr.sgml : 20250728 20250728071522 ACCESSION NUMBER: 0001558370-25-009636 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20250728 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250728 DATE AS OF CHANGE: 20250728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 251152930 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 pmn-20250728x8k.htm 8-K PROMIS NEUROSCIENCES INC._July 28, 2025 0001374339 false 0001374339 2025-07-28 2025-07-28 ​ ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) ​ ​ ​ ​ ​ ​ ​ Canada      001-41429      98-0647155 (State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.) ​ ​ ​ Suite 200 , 1920 Yonge Street , Toronto , Ontario      ​      M4S 3E2 (Address of principal executive offices)   ​ ​ (Zip Code) ​ Registrant’s telephone number, including area code: ( 416 ) 847-6898 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ Title of Each Class      Trading Symbol(s)      Name of Each Exchange on Which Registered Common Shares, no par value per share PMN The Nasdaq Capital Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ Item 1.01 Entry into a Material Definitive Agreement. PIPE Offering ​ On July 28, 2025, ProMIS Neurosciences Inc. (the “ Company ”) entered into a securities purchase agreement (the “ PIPE Purchase Agreement ”) with existing institutional investors, each of which qualifies as an “ac